We are live on ! Find out more
VKTXW

Viking Therapeutics, Inc.
VKTXW

Delisted

VKTXW was delisted on the 8th of April, 2021.

Back to rankings

3 hedge funds and large institutions have $632K invested in Viking Therapeutics, Inc. in 2020 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

85% more capital invested

Capital invested by funds: $342K → $632K (+$290K)

0% more funds holding

Funds holding: 3 → 3 (0)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$770

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$18.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
PWAM
1
Park West Asset Management
California
$554K – – –
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$62K -$18.5K -3,503 -25%
UBS Group
3
UBS Group
Switzerland
$16K +$770 +146 +5%

VKTXW Hedge Fund Activity: Q2 2020 in Review

3 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics, Inc. (VKTXW) for Q2 2020, worth a combined $632K — up 85% from $342K a quarter earlier.

Fund positioning in VKTXW was balanced in Q2 2020: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was UBS Group, adding an estimated $770. The largest seller was Susquehanna International Group, cutting an estimated $18.5K.

  • 3 institutional investors held Viking Therapeutics, Inc. (VKTXW) as of Q2 2020, unchanged from Q1 2020.
  • Funds reported $632K of Viking Therapeutics, Inc. stock for Q2 2020, up 85% quarter-over-quarter.
  • 0 funds opened new Viking Therapeutics, Inc. positions in Q2 2020 and 0 closed out.
  • The largest Viking Therapeutics, Inc. buyer in Q2 2020 was UBS Group, an estimated $770 added.
  • The largest Viking Therapeutics, Inc. seller in Q2 2020 was Susquehanna International Group, an estimated $18.5K sold.

Based on aggregated 13F filings for Q2 2020.